Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06466122
Title Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kerry Rogers
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.